Nektar Therapeutics (NKTR) — Cash Flow Reinvestment Rate
Nektar Therapeutics (NKTR) has a Cash Flow Reinvestment Rate of 0.93x as of June 2018, reinvesting $897.05 Million (capex $2.75 Million plus investments $-894.30 Million) from operating cash flow of $959.64 Million. See NKTR free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Nektar Therapeutics Cash Flow Reinvestment Rate (1997–2018)
Historical reinvestment intensity for Nektar Therapeutics across 4 annual periods. For the full cash flow conversion analysis, see Nektar Therapeutics cash conversion from operations.
Annual Cash Flow Reinvestment Rate for Nektar Therapeutics (1997–2018)
Year-by-year capital reinvestment analysis for Nektar Therapeutics. See Nektar Therapeutics (NKTR) financial flexibility to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2018 | 1.93x | $1.38 Billion | $718.21 Million | $14.24 Million | ▲ +269.5% |
| 2009 | 0.52x | $20.70 Million | $39.74 Million | $20.70 Million | ▲ +132.4% |
| 2007 | 0.22x | $32.80 Million | $146.30 Million | $32.80 Million | ▼ -93.5% |
| 1997 | 3.47x | $17.26 Million | $4.98 Million | $17.26 Million | — |